Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | HMGCR | P04035 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.41 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5141831 | 0.89 | ACHE (0.48) | ACHEALOX5PTGS2 | |
| SCHEMBL13296654 | 0.87 | ALOX5 (0.54) | ACHEALOX5PTGS2 | |
| SCHEMBL8009626 | 0.82 | CYP1A2 (0.44) | PDE3BPDE3AHMGCRALDH1A1SMN1; SMN2 | |
| SCHEMBL5141794 | 0.81 | ACHE (0.54) | ACHEPDE3BPDE3AERN1ALDH1A1 | |
| SCHEMBL7114104 | 0.80 | ALOX5 (0.53) | PDE3BPDE3AHMGCRALOX5CYP3A4 | |
| SCHEMBL918847 | 0.80 | PTGS2 (0.59) | PDE3BPDE3AHMGCRALDH1A1KDM4E | |
| SCHEMBL31187890 | 0.80 | ACHE (0.48) | ACHEHMGCRALOX5ERN1ALDH1A1 | |
| SCHEMBL31187944 | 0.80 | ACHE (0.48) | ACHEERN1ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL10752271 | 0.79 | ALOX5 (0.44) | ACHEALOX5CRHR1PTGS2 | |
| SCHEMBL919348 | 0.78 | PTGS2 (0.42) | PDE3BPDE3AHMGCRALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ACHE 1708/4885PDE3B 359/4885PDE3A 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.